On April 28, 2021, upon the recommendation of the governance and nomination committee of the Board of Directors of Trillium Therapeutics Inc., the Board appointed Scott Myers as a member of the Board, effective April 28, 2021. Mr. Myers was the Chief Executive Officer and served on the board of directors of AMAG Pharmaceuticals Inc., where he led its turnaround and strategic exit to Covis Pharma, S.à.r.l., in November 2020. Mr. Myers has served as Chairman of the board of directors of Rainier Therapeutics Inc., from June 2018 to January 2020, and served as its Chief Executive Officer from September 2018 to January 2020. On April 28, 2021, Robert Kirkman and Thomas Reynolds delivered their resignations from the Board and all committees thereof, effective upon the appointment of Mr. Myers.